about
Cardiovascular KATP channels and advanced agingThe multiple faces of RAGE--opportunities for therapeutic intervention in aging and chronic diseaseRAGE modulates hypoxia/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK-3beta signaling pathways.RAGE regulates the metabolic and inflammatory response to high-fat feeding in miceGlutaminolysis and Transferrin Regulate Ferroptosis.Cardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia.Acute administration of n-3 rich triglyceride emulsions provides cardioprotection in murine models after ischemia-reperfusionAldose reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats.Aldose reductase pathway contributes to vulnerability of aging myocardium to ischemic injury.Morphological Changes and Immunohistochemical Expression of RAGE and its Ligands in the Sciatic Nerve of Hyperglycemic Pig (Sus Scrofa)RAGE Suppresses ABCG1-Mediated Macrophage Cholesterol Efflux in Diabetes.Human aldose reductase expression accelerates atherosclerosis in diabetic apolipoprotein E-/- miceSmall Molecule Inhibition of Ligand-Stimulated RAGE-DIAPH1 Signal TransductionEmerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway.Aldose reductase, oxidative stress and diabetic cardiovascular complicationsAldose Reductase Acts as a Selective Derepressor of PPARγ and the Retinoic Acid Receptor.Insulin resistance: metabolic mechanisms and consequences in the heart.Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond.Aldose reductase drives hyperacetylation of Egr-1 in hyperglycemia and consequent upregulation of proinflammatory and prothrombotic signals.RAGE, glomerulosclerosis and proteinuria: roles in podocytes and endothelial cells.New York University School of Medicine Drug Development Educational Program: 2-Year Benchmark.Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model.Advanced glycation endproducts: from precursors to RAGE: round and round we go.The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes.Unlocking the biology of RAGE in diabetic microvascular complicationsCellular mechanisms and consequences of glycation in atherosclerosis and obesity.Mechanisms of transcription factor acetylation and consequences in hearts.Glycation & the RAGE axis: targeting signal transduction through DIAPH1.The AGE-RAGE axis in an Arab population: The United Arab Emirates Healthy Futures (UAEHFS) pilot study.The UAE healthy future study: a pilot for a prospective cohort study of 20,000 United Arab Emirates nationals.Aldose reductase modulates acute activation of mesenchymal markers via the β-catenin pathway during cardiac ischemia-reperfusion.The Formin, DIAPH1, is a Key Modulator of Myocardial Ischemia/Reperfusion Injury.Targeted drug discovery and development, from molecular signaling to the global market: an educational program at New York University, 5-year metrics.Training scientists as future industry leaders: teaching translational science from an industry executive's perspective.Patterns of tobacco use in the United Arab Emirates Healthy Future (UAEHFS) pilot study.Human Aldose Reductase Expression Prevents Atherosclerosis Regression in Diabetic MiceThe receptor for advanced glycation end products (RAGE) and DIAPH1: unique mechanisms and healing the wounded vascular systemMetabolic dysfunction in Emirati subjects in Abu Dhabi: Relationship to levels of soluble RAGEsReceptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and Animal ModelsEnhanced glycolysis and HIF-1α activation in adipose tissue macrophages sustains local and systemic interleukin-1β production in obesity
P50
Q28076393-635B7147-4363-4788-98E9-7596645E1EFAQ28830568-AD8EF5B4-9305-4E24-8F05-1464115857E3Q33559727-68E49ABD-8395-4DD0-AD1E-43B0208894DDQ33646761-280202A7-65C5-4117-9F60-6176D5E4F636Q34044434-C643AA92-1312-481C-BA34-CB7E60531898Q34431401-D317FD01-8C0D-48BA-B61E-35BA4245EDA6Q34822757-1C5F6A12-75F5-49E9-9952-C2044998FC1EQ35090344-3987B8DA-A635-4484-9DE5-BDBACCF8CB9AQ35131902-6FAB36BD-F966-43D7-888D-C92D223F9764Q35165597-D84386DF-9FC8-4A1E-87B9-994B87C21768Q35740332-4399A9FC-F013-4ACF-AAE0-7D4BE1AC92BEQ35753067-C19B7FCE-C12D-42D9-9542-9138315C6DA4Q35943768-FD1E73D6-BC14-4354-861E-918CC848DDFFQ36207823-73866D5E-96E7-4779-B3B5-BB66DF3B7683Q36777049-8AD501B5-8169-4547-9FBA-9E9BE95E27B0Q36784506-F68BC7D6-5839-490C-854F-B8B76E170F57Q36821424-ACE7C00A-FDBC-4133-9FCF-299AC3800423Q37291206-CF09925E-DC2B-404E-BE87-070E7EE188D8Q37510157-36A1FF93-8A57-4E9C-836C-F31ADE0813AAQ37603949-B52C6DB0-5F97-4F51-B157-78F8BCCFD5E7Q37700650-041701EB-7FF1-4399-AD1B-3E8C91606CB4Q37751655-FA54856F-7EC1-4DED-8A52-D5FBC5662584Q37801314-E6E6F475-148E-4572-90CF-CD8145ACEF96Q38023062-823A2119-E883-49DB-AD70-B4624B821561Q38134924-912F02F8-5E0A-4792-A12C-467261451390Q38831558-B19404D8-750E-45D8-8478-37FE7A5348C6Q38932625-07FD0081-E203-486D-9358-249666AB4871Q39038218-587A5B88-5B3F-47D9-96D0-28E921C0BFECQ47162406-4273E5B0-7FBC-40C9-B232-E4627F625041Q47179284-4E99D0CD-F6C6-4F1A-A032-F0A1D9CEAB4EQ47346466-18E4AA49-3D43-40D9-8507-EA456C029EFBQ49844367-431D765E-4718-4440-A851-7B605CBBDD55Q52587091-06E38CE7-F309-4D78-B53D-AF41698DD236Q52587095-C80AEAAA-0B9C-4A80-826D-CC70561BC7DAQ55207795-318DF456-4B4E-49CF-89B0-DDF64ED9DBE9Q56971664-1FBE2C31-60F5-40A3-BA63-EF41CF519D90Q57457290-0C34426A-78B0-4170-93E4-9207B38A6032Q64097199-BE060343-F046-4CCF-B427-9AD5A7B7B325Q90643374-8C1E8C51-82E4-4928-B4DC-3138B2360D37Q90713969-E99B3071-384B-4093-83F7-9D96DABB19FD
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Ravichandran Ramasamy
@en
Ravichandran Ramasamy
@nl
type
label
Ravichandran Ramasamy
@en
Ravichandran Ramasamy
@nl
prefLabel
Ravichandran Ramasamy
@en
Ravichandran Ramasamy
@nl
P31
P496
0000-0002-3666-3346